Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors	Advanced Solid Tumors	Recruiting	Phase 1 / Phase 2	2026-09-02		NCT06795412

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Merck Sharp & Dohme LLC	650
Pyxis Oncology, Inc	3

22 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Centre Léon Bérard	Lyon	France	77
Dana-Farber Cancer Institute	Boston	United States	626
Hopital Saint - Andre - CHU de Bordeaux	Bordeaux	France	1
Hospital Clínico Universitario de Valencia	Valencia	Spain	58
Hospital Universitario 12 de Octubre	Madrid	Spain	359
Hospital Universitario Ramón y Cajal	Madrid	Spain	87
Hospital Universitario Vall D'Hebron	Barcelona	Spain	86
Hôpital de La Timone	Marseille	France	13
Institut Gustave Roussy	Villejuif	France	54
Massachusetts General Hospital	Boston	United States	1015
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Moffitt Cancer Center	Tampa	United States	523
NEXT Oncology Houston	Houston	United States	5
NEXT Virginia	Fairfax	United States	83
Sarcoma Oncology Center	Santa Monica	United States	17
START Madrid - Hospital Universitario Fundación Jiménez Díaz	Madrid	Spain	6
Stephenson Cancer Center - University of Oklahoma	Oklahoma City	United States	1
University of California San Diego	San Diego	United States	22
University of Chicago	Chicago	United States	312
University of Pennsylvania	Philadelphia	United States	507
University of Pittsburgh Medical Center	Pittsburgh	United States	63
University of Texas - M.D. Anderson Cancer Center	Houston	United States	1

Clinical trials